Key Points
- Insider purchase: Brett Matthew Hall bought 2,298 shares at an average price of $4.57 on Jan. 15 for $10,501.86, increasing his stake 0.61% to 376,496 shares (worth ≈ $1.72M).
- Stock context: IMRX opened at $4.58, trading below its 50‑day ($6.37) and 200‑day ($5.78) moving averages with a market cap of ≈ $295.7M; the company recently reported a quarterly EPS of -$0.38 (slightly missing estimates) and is forecast to post -1.86 EPS for the year.
- Analyst and ownership snapshot: Ratings are mixed but the consensus is a "Moderate Buy" with a $16.50 price target, and institutional investors own about 67.65% of the stock.
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall bought 2,298 shares of the company's stock in a transaction dated Thursday, January 15th. The shares were acquired at an average price of $4.57 per share, for a total transaction of $10,501.86. Following the acquisition, the insider owned 376,496 shares in the company, valued at approximately $1,720,586.72. This represents a 0.61% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Immuneering Price Performance
NASDAQ:IMRX opened at $4.58 on Friday. The firm's 50-day moving average price is $6.37 and its 200-day moving average price is $5.78. The company has a market capitalization of $295.73 million, a PE ratio of -2.57 and a beta of 0.48. Immuneering Corporation has a 1-year low of $1.10 and a 1-year high of $10.08.
Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Equities analysts anticipate that Immuneering Corporation will post -1.86 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Immuneering during the third quarter valued at $35,000. Future Financial Wealth Managment LLC purchased a new position in Immuneering in the 3rd quarter worth about $35,000. Mercer Global Advisors Inc. ADV bought a new position in Immuneering during the 3rd quarter valued at about $70,000. Moors & Cabot Inc. purchased a new stake in shares of Immuneering during the 3rd quarter valued at about $77,000. Finally, Virtu Financial LLC purchased a new stake in shares of Immuneering during the 3rd quarter valued at about $98,000. Hedge funds and other institutional investors own 67.65% of the company's stock.
Analyst Ratings Changes
Several analysts recently weighed in on the company. Leerink Partners started coverage on Immuneering in a research report on Friday, October 31st. They set an "outperform" rating and a $15.00 price objective for the company. Mizuho set a $12.00 target price on Immuneering in a report on Wednesday, October 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Immuneering in a report on Monday, December 29th. Wall Street Zen lowered Immuneering from a "hold" rating to a "sell" rating in a research report on Saturday, December 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Immuneering in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $16.50.
Get Our Latest Stock Analysis on IMRX
Immuneering Company Profile
(
Get Free Report)
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
